Diamedica Therapeutics INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
DiaMedica Therapeutics' 2025 annual report details progress in DM199 clinical trials for preeclampsia and stroke, alongside financial losses and enrollment challenges.
NASDAQ
DiaMedica Therapeutics focuses on advancing its DM199 clinical programs for acute ischemic stroke and preeclampsia, with key milestones expected in 2025.
NASDAQ
DiaMedica Therapeutics Inc. outlines the details of its registered voting common shares, including voting, dividend, and liquidation rights, as well as anti-takeover provisions.